Q1 Earnings Forecast for Annexon Issued By HC Wainwright

Annexon, Inc. (NASDAQ:ANNX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Annexon in a research note issued on Tuesday, March 4th. HC Wainwright analyst A. Fein expects that the company will earn ($0.33) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $30.00 price target on the stock. The consensus estimate for Annexon's current full-year earnings is ($0.96) per share. HC Wainwright also issued estimates for Annexon's FY2025 earnings at ($1.31) EPS, FY2026 earnings at ($1.37) EPS, FY2027 earnings at ($0.78) EPS and FY2028 earnings at ($0.28) EPS.

A number of other research firms also recently commented on ANNX. Needham & Company LLC restated a "buy" rating and issued a $16.00 price objective on shares of Annexon in a report on Tuesday, March 4th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has a consensus rating of "Buy" and a consensus price target of $15.80.

Annexon Stock Performance

Shares of ANNX traded up $0.06 during trading hours on Friday, hitting $2.67. The stock had a trading volume of 1,029,837 shares, compared to its average volume of 1,801,712. The company's fifty day simple moving average is $3.70 and its 200 day simple moving average is $5.30. Annexon has a 12-month low of $2.30 and a 12-month high of $8.40. The firm has a market cap of $292.93 million, a P/E ratio of -2.54 and a beta of 1.14.

Remove Ads

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.05).

Institutional Investors Weigh In On Annexon

A number of institutional investors have recently modified their holdings of the stock. Parkman Healthcare Partners LLC raised its position in shares of Annexon by 0.5% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company's stock valued at $1,945,000 after acquiring an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of Annexon by 1.6% during the third quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company's stock worth $945,000 after purchasing an additional 2,450 shares during the period. GSA Capital Partners LLP lifted its position in shares of Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company's stock worth $205,000 after buying an additional 3,355 shares during the last quarter. E Fund Management Co. Ltd. lifted its position in shares of Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock worth $79,000 after buying an additional 4,086 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Annexon by 6.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 63,402 shares of the company's stock valued at $325,000 after buying an additional 4,092 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.